F-1: Davion Healthcare to Direct List on NASDAQ

Davion Healthcare Plc, a pre-revenue Irish company specializing in non-invasive home diagnostic tests, is pursuing a direct listing on the NASDAQ Global Market under the ticker DAVI.

Summary

• Davion Healthcare Plc is an Irish Public Limited Company focused on developing and commercializing non-invasive home diagnostic tests for early detection of health anomalies, including cancers.
• The company is undertaking a direct listing of 25,000,000 Ordinary Shares on the NASDAQ Global Market under the ticker symbol DAVI, with an anticipated opening trading price of $10.00 per share, implying a total market capitalization of $250 million.
• No new securities are being offered by the company or any selling shareholders in this registration, and Davion will not receive any proceeds from this direct listing.
• The flagship product, BreastCheck, is a non-invasive home test for breast abnormalities, which is FDA registered in the USA, and holds CE mark in the EU and UKCA mark in the UK.
• Davion Healthcare reported an operating loss of €1,320,353 for the year ended December 31, 2024, an improvement from the €5,308,332 operating loss in 2023.
• The company has not generated any revenue to date and does not expect to do so until the second half of 2025 at the earliest.
• A significant agreement was secured with NeuRX Health Inc. in 2024 for the global manufacturing and distribution of BreastCheck, valued at $120 million USD, including $20 million in cash payments over 12 months and $100 million in NeuRX shares.
• The NeuRX Health Inc. agreement also includes ongoing royalty payments of $5 USD for every BreastCheck manufactured, with a minimum of $5 million USD in royalty payments for the first 12 months.
• An independent third-party valuation in 2024 estimated the fair value of the company's intellectual property at €260 million, significantly exceeding its carrying value of €65 million.
• The company's liquidity has been limited, relying on financial support from its CEO, Jack Kaye, who has provided all funding to date.
• Davion Healthcare qualifies as an emerging growth company and a foreign private issuer, allowing for reduced reporting obligations under U.S. securities laws.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company is pre-revenue and has incurred losses, the significant licensing agreement with NeuRX Health Inc., the substantial fair value revaluation of intellectual property, and the successful regulatory approvals for its products provide a strong foundation for future commercialization and revenue generation. The direct listing on NASDAQ also offers increased visibility and potential access to capital. However, the pre-revenue status, reliance on CEO funding, and inherent risks of a new market entrant temper the overall sentiment.

Positives

• Secured a significant global manufacturing and distribution license agreement for BreastCheck with NeuRX Health Inc. valued at $120 million USD, including cash payments and NeuRX shares.
• The NeuRX agreement includes ongoing royalty payments of $5 USD per unit manufactured, with a minimum of $5 million USD in the first year.
• Flagship product, BreastCheck, and other pipeline products (FootFlow, Testic, ThermaDerm) have successfully secured regulatory approvals in the USA (FDA), EU (CE mark), and UK (UKCA mark).
• An independent third-party valuation in 2024 estimated the fair value of the company's intellectual property at €260 million, substantially improving the company's financial position despite IFRS accounting at cost.
• Operating loss significantly reduced from €5,308,332 in 2023 to €1,320,353 in 2024, reflecting a decrease in R&D and administrative expenses.
• The company possesses its own IP, patents, and technology, and currently faces no known competitors utilizing like-technologies for its core products.
• The direct listing on NASDAQ Global Market is expected to provide market visibility and access to capital for future growth.

Negatives

• The company is currently pre-revenue and does not expect to generate revenue until the second half of 2025 at the earliest.
• Davion Healthcare has incurred significant operating losses, with a net loss of €1,320,353 in 2024 and €5,308,332 in 2023.
• The company has historically relied exclusively on the personal financial support of its CEO, Jack Kaye, for all funding.
• As of June 1, 2025, the company has no full-time employees, relying on outsourced R&D, manufacturing, and design.
• Current liabilities exceeded current assets by €31,607 as of December 31, 2024, indicating limited liquidity.
• The company has limited experience in high-volume manufacturing and brand building, which are critical for future success.
• The company is subject to risks associated with being an emerging growth company and a foreign private issuer, including less extensive and less timely SEC reporting compared to U.S. domestic issuers.

Risks

• Potential cost increases or disruptions in the supply of raw materials and components for BreastCheck, especially from single-source suppliers.
• Inability to successfully establish, maintain, and strengthen the BreastCheck brand, or harm to brand reputation from negative publicity or unfavorable third-party reviews.
• Dependence on the continuing efforts of executive officers and key employees; loss of their services could severely disrupt operations.
• Future growth is dependent on consumer demand for and willingness to adopt BreastCheck, which is subject to economic conditions and market acceptance.
• Exposure to product liability claims if BreastCheck does not perform as expected or malfunctions, potentially harming financial condition and reputation.
• Risk of patent or trademark infringement claims from competitors, leading to costly litigation, cessation of sales, or licensing fees.
• Inability to prevent unauthorized use of intellectual property, which could harm business and competitive position.
• Risks associated with strategic alliances or acquisitions, including sharing proprietary information, non-performance by third parties, and diversion of management resources.
• Failure to manage growth effectively as operations expand, potentially affecting marketing and sales success.
• Failure to maintain an effective system of internal control over financial reporting, which could affect financial reporting accuracy and investor confidence.
• Impact of financial or economic crises, including decreased consumer confidence, on business, financial condition, and results of operations.
• Uncertainty regarding the classification as a Passive Foreign Investment Company (PFIC) for U.S. federal income tax purposes, which could result in adverse tax consequences for U.S. holders.
• Difficulties in protecting shareholder interests and limited ability to protect rights through U.S. courts due to incorporation under Irish law.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Delays in the manufacturing and launch of commercial production for BreastCheck and other pipeline products could adversely affect growth prospects.
• Intense competition in the industry from existing diagnostic methods and potential new entrants with similar non-invasive technologies.
• Inability to keep up with changes in product technology and adapt research and development efforts, leading to reduced competitiveness.

Future Outlook

Davion Healthcare anticipates ongoing operating losses and negative cash flows until the commercial rollout of its home testing devices, particularly BreastCheck, in the second half of 2025. Market acceptance of these devices will be critical for revenue generation. The company expects to shift its focus from development to commercialization, with significant R&D investments leading to increased revenue. Management is confident in future profitability due to the NeuRX Health Inc. licensing agreement and planned product commercialization.

Management Comments

• Our mission is to afford early non-invasive detection of possible physical abnormalities including breast growths, testicular growths, blood flow and more.
• Our strength as a Company at this early state is twofold, that we possess our own IP, patents and technology; and that to date, there are no other known competitors attempting to utilize like-technologies.
• The Board is confident that with the BreastCheck product set to be commercialized in the second half of 2025, coupled with the licensing agreement, the Company is well-positioned for future profitability.
• The significant R&D ongoing investments are expected to result in increased revenue as the Company shifts its focus from development to commercialization.
• With its current capitalization, our Chief Executive Officer's ongoing financial support, and future contractual inflows, the Company believes that it has sufficient financial resources to meet its obligations for at least the next 12 months.

Industry Context

Davion Healthcare operates in the rapidly evolving non-invasive home diagnostic test market, targeting early detection of health anomalies, including cancers. This market addresses a significant medical need, particularly for breast cancer, which is the most common cancer among women globally. The company's focus on affordable, home-based solutions positions it to potentially disrupt traditional diagnostic methods like mammograms, serving a large, underserved market of individuals seeking private health monitoring. The increasing incidence of breast cancer and diabetes globally underscores the demand for accessible early detection tools, aligning with Davion's product pipeline (BreastCheck, FootFlow, Testic). The company's strategy of leveraging third-party R&D and outsourced manufacturing allows for agility in a competitive landscape, while its proprietary IP provides a competitive edge against known technologies.

Comparison to Industry Standards

• Davion Healthcare's BreastCheck is positioned as a non-invasive adjunct to established procedures like mammography, rather than a direct replacement. This approach acknowledges the current gold standard while offering a complementary, accessible home-based solution.
• The company claims BreastCheck has been proven to be a reliable guide in the first stage identification of potential breast abnormalities, with an accuracy level stated to be the same as a mammogram. This claim, if substantiated by independent clinical data, would be a significant differentiator in the diagnostic market.
• The business model of using third-party R&D (universities and specialized companies) and outsourced manufacturing is common for early-stage medical device companies, allowing for lower overheads and specialized expertise, similar to many biotech startups.
• The licensing agreement with NeuRX Health Inc. for global manufacturing and distribution is a strategic move to scale commercialization, a common practice for companies without extensive in-house manufacturing and distribution networks, comparable to partnerships seen with larger pharmaceutical or medical device companies.
• The company's pre-revenue status and reliance on CEO funding are typical for early-stage medical technology companies, which require substantial upfront investment in R&D and regulatory approvals before commercialization.

Management Changes

Corporate Governance

Related Party Transactions

• Malbrite Ltd, a company owned by CEO Jack Kaye, has provided all financial support for the company since its inception.
• For the year ended December 31, 2023, the company incurred €1,100,000 in management fees with Malbrite Limited and Kurdam Inc., companies controlled by Jack Kaye.
• For the year ended December 31, 2024, the company issued 598,246 shares of stock to its officers in exchange for amounts due to them of €5,600,000.
• For the years ended December 31, 2024 and 2023, the company incurred €400,000 and €600,000, respectively, in director fees by David Paul Alexander Over, a director, with the balance payable paid in full with share issuances.
• For the year ended December 31, 2023, the company paid approximately €287,000 for marketing services to Tulk House International Limited, a company controlled by David Paul Alexander Over.
• For the year ended December 31, 2023, the company incurred €77,415 in management fees and €1,707,178 in research and development costs with Rallinson Limited, a company controlled by Jack Kaye.
• For the year ended December 31, 2023, the company incurred €556,279 in research and development costs with Malbrite Limited, a company controlled by Jack Kaye.

Stakeholder Impact

• **Shareholders:** Existing shareholders will gain liquidity through the direct listing on NASDAQ. Future capital raises could dilute existing shareholders. The equity incentive plan for executives aligns management interests with shareholder value.
• **Employees:** The company currently has no full-time employees, relying on outsourced functions. Future growth and commercialization may lead to hiring, but current impact is minimal.
• **Customers:** The commercialization of BreastCheck and other home diagnostic tests aims to provide affordable, non-invasive early detection tools, potentially improving health outcomes and accessibility for a large market.
• **Suppliers:** The company is dependent on single-source suppliers for certain components, posing a risk of supply chain disruptions and cost increases.
• **Creditors:** Conversion of amounts owed to related parties and other creditors into equity has reduced liabilities, but the company's limited liquidity and reliance on CEO funding highlight ongoing financial dependence.

Next Steps

• Complete and sign the full Global Manufacturing and Distribution Licence agreement with NeuRX Health Inc. by the commencement of the third quarter of 2025.
• Commence commercialization activities for BreastCheck in the second half of 2025.
• Begin generating revenue from product licensing agreements and ongoing sales royalties in the second half of 2025.
• Potentially pursue additional financing opportunities, including a registered public offering, following the NASDAQ listing.
• Continue product development for other non-invasive home test products like FootFlow and Testic, with planned launches in 2025.
• The Audit Committee will oversee financial reporting, internal controls, external auditors, and legal/regulatory compliance.

Key Dates

Recommendation

Davion Healthcare Plc presents a compelling long-term growth story with its innovative non-invasive diagnostic products and significant licensing agreement with NeuRX Health Inc. The direct listing on NASDAQ provides much-needed liquidity and market visibility. However, the company is still in a pre-revenue stage, heavily reliant on its CEO for funding, and faces substantial execution risks related to commercialization, brand building, and supply chain management. While the fair value of its IP is impressive, it is not yet reflected in revenue or profitability. A 'hold' recommendation is appropriate for seasoned investors, acknowledging the high potential but also the significant risks and the need for successful execution in the coming years before a 'buy' recommendation could be justified. Investors should monitor the commercial launch of BreastCheck, the realization of revenue streams, and the company's ability to manage its growth and liquidity.

Keywords

Davion Healthcare, DAVI, Direct Listing, NASDAQ, BreastCheck, Non-invasive diagnostic, Home test, Breast cancer detection, Medical devices, Healthcare technology, SEC F-1 filing, NeuRX Health Inc., Intellectual property, Regulatory approval, FDA, CE mark, UKCA mark, Pre-revenue company, Financial reporting, Corporate governance, Risk factors